Group 1 - GE Healthcare Technologies (GEHC.US) is exploring various options, including the potential sale of its Chinese subsidiary, with valuations possibly reaching several billion dollars [1] - The company is working with advisors to assess the prospects of its business in China, although no final decisions on timing or scale have been made [1] - Other multinational companies, such as Starbucks (SBUX.US) and General Mills (GIS.US) with Häagen-Dazs, are also considering divesting their operations in China due to intense local competition [1] Group 2 - General Electric (GE) divested its medical equipment business in 2023, and GE Healthcare's stock has decreased by 2% this year, with a current valuation of approximately $35 billion [2] - GE Healthcare's product offerings include imaging scans, ultrasound, patient care solutions, and pharmaceutical imaging agents [2] - China is GE Healthcare's second-largest market, employing around 7,000 people, with projected revenues of $2.4 billion for 2024, reflecting a 15% decline from the previous year [2]
传GE Healthcare(GEHC.US)考虑出售中国业务 估值或达数十亿美元